 |
|
|
42nd Annual Meeting
American Society of Clinical Oncology
June 2 - 6, 2006 | Atlanta, Georgia
|
 |
|
Highlights from ASCO 2006
The results of more than 3,700 cancer research studies are being presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, GA., from June 2 - 6, 2006. Nearly 25,000 cancer specialists from around the world are gathering to discuss the latest advances in cancer care, treatment, and prevention.
|
|
Elderly Benefit From Chemotherapy After Surgery for Early Non-Small Cell Lung Cancer
(Posted: 06/03/2006, Reviewed: 05/01/2007) - Elderly patients with early-stage non-small cell lung cancer who received chemotherapy following surgery lived longer than those who'd had surgery alone, without an increase in treatment-related toxicity or hospitalization, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
Lapatinib (Tykerb®) Plus Capecitabine Delays Progression of HER2-Positive Breast Cancer
(Posted: 06/03/2006) - Combining the experimental targeted agent lapatinib with the drug capecitabine delayed the progression of breast cancer for nearly twice as long as did treatment with capecitabine alone in patients with advanced breast cancer that had progressed following treatment with trastuzumab (Herceptin®), according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
Exemestane Following Tamoxifen Reduces Breast Cancer Recurrences and Prolongs Survival
(Posted: 03/10/2004, Updated: 06/04/2006) - Longer follow-up data from a large international phase III trial of postmenopausal women with breast cancer who switched to the drug exemestane (Aromasin®) after several years on tamoxifen confirm a delay in disease progression and also show a survival advantage, compared to women who stayed on tamoxifen, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
Cisplatin-Based Chemotherapy Improves Survival in Non-Small Cell Lung Cancer
(Posted: 06/04/2006) - Combined data from five large randomized clinical trials confirmed that cisplatin-based chemotherapy extends survival for patients with stage II or stage III non-small cell lung cancer, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
Motexafin Gadolinium Slows Brain Damage from the Spread of Non-Small Cell Lung Cancer
(Posted: 06/04/2006) - The addition of the drug motexafin gadolinium to whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer significantly delayed the progression of neurological damage, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
Chemotherapy Superior to Whole-Abdominal Radiation Therapy for Uterine Sarcoma
(Posted: 06/27/2006) - Chemotherapy with cisplatin and ifosfamide was more effective than whole-abdominal radiation therapy at extending survival in patients with uterine sarcoma, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
Sunitinib Effective Against GIST After Imatinib Fails
(Posted: 08/05/2006) - Patients with gastrointestinal stromal tumors (GIST) for whom the drug imatinib was no longer effective survived four times longer without progressive disease on the drug sunitinib, compared to similar patients taking a placebo, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology. Overall survival was also significantly improved with sunitinib.
Sunitinib and Temsirolimus: Two New Targeted Drugs for Advanced Kidney Cancer
(Posted: 06/05/2006, Reviewed: 07/09/2007) - In separate clinical trials, two new targeted drugs - sunitinib (Sutent®) and temsirolimus - have shown positive results in patients with advanced kidney cancer, offering new standards of care, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
Thalidomide Helps Elderly Multiple Myeloma Patients to Live Longer
(Posted: 06/05/2006, Reviewed: 10/06/2007) - Elderly patients with multiple myeloma who were treated with the drug thalidomide in addition to standard chemotherapy lived 15 to 21 months longer on average than patients who received either high doses of a standard drug followed by a stem cell transplant or standard chemotherapy alone, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
Gemcitabine Plus Standard Chemoradiation Improves Survival in Patients with Pancreatic Head Tumors
(Posted: 06/05/2006) - Adding gemcitabine to a standard chemoradiation regimen improved overall survival in patients with the most common kind of pancreatic tumors: those located in the head of the pancreas, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
Lower Dose of Thalidomide May Be Just as Effective in Multiple Myeloma
(Posted: 06/07/2006) - Cutting the daily dose of the drug thalidomide from 400 mg to 100 mg significantly reduced the drug's potentially severe side effects in patients with multiple myeloma that had come back or stopped responding to treatment, and without a significant impact on survival, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
Rituximab Helps Patients with Recurrent Lymphomas
(Posted: 10/26/2005, Updated: 11/01/2006) - Two studies from Germany showed the targeted therapy rituximab (Rituxan®) to be effective in treating recurrent or refractory follicular and mantle cell lymphomas. Findings from these studies were presented at the 2005 and 2006 annual meetings of the American Society of Clinical Oncology.
Lenalidomide Effective in Multiple Myeloma
(Posted: 06/28/2006, Reviewed: 11/27/2007) - Combining lenalidomide with dexamethasone delayed the progression of advanced multiple myeloma for more than twice as long as did dexamethasone alone in patients whose disease had come back or stopped responding to other treatments, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
Fewer CT Scans Needed after Surgery for Low-Risk, Early-Stage Testicular Cancer
(Posted: 06/28/2006, Reviewed: 04/17/2007) - During the follow-up period after surgery, two computed tomography (CT) scans were just as effective as five CT scans in detecting relapse for patients with a certain kind of low-risk, early-stage testicular cancer, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
|
|
|
